Quarterly Sales (Approved)
August 4, 2020
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Quarterly Sales for XPOVIO (Selinexor) (FDA-approved drug)
WHAT IS THE CATALYST EVENT?
On its Q1 2020 investor call, KPTI reported slightly decreased revenue for XPOVIO. Management noted challenges with new patient starts in March given Covid pandemic, and suggested that April saw some renewed prescription growth. The March numbers were disappointing because KPTI began the month with positive Boston results in earlier multiple myeloma patients, which might have fueled further growth of XPOVIO even before FDA approval in less heavily pre-treated patients.
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Q1 2020 sales (See image below)
2018: Selinexor and dexamethasone in multiple myeloma. Lancet Oncol. 2018;19(3):e146. doi:10.1016/S1470-2045(18)30089-5
2018: Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood. 2018;131(8):855-863. doi:10.1182/blood-2017-08-797886
2018: Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018;36(9):859-866. doi:10.1200/JCO.2017.75.5207
2019: Selinexor for Refractory Multiple Myeloma. N Engl J Med. 2019;381(20):1977. doi:10.1056/NEJMc1912625
MECHANISM OF ACTION/RATIONALE
Nuclear export inhibitor
Inhibits XPO1 (see slide 5), which is believed to impact tumor cells in 3 ways
1. Increases nuclear levels and activation of tumor suppressor proteins
2. Traps oncoprotein mRNA in the nucleus leading to reduced oncoprotein levels
3. Retains activated glucocorticoid receptor in the nucleus
Updated by HC
KPTI, XPOVIO, SELINEXOR, Multiple myeloma (Penta-Refractory), STORM
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post